Table 2 Logistic regression analysis of parameters predicting overall [¹⁸F]PSMA-1007-PET/CT scan positivity: univariable analysis

Injected activity

 + 1 unit

1 (0.99–1.01); 0.66

Interval injection-start scan

 + 1 min

1.01 (0.99–1.04); 0.43

Neoadjuvant treatment

Yes versus no

4.39 (0.61–31.75); 0.14

Primary treatment

EBRT^b versus RP^c

3.52 (0.43–29.07); 0.24

Pathological primary tumour staging

 + 1 stage

1.26 (0.53–3); 0.61

Pathological regional lymph node staging

pN1 versus pN0

4.64 (0.89–24.16); 0.07

Positive surgical margin

Global test

p value = 0.43

Gleason score

 + 1 level

1.2 (0.82–1.76); 0.35

Lymph nodes removed

Yes versus no

0.38 (0.14–1.08); 0.07

Number lymph nodes removed

 + 1 lymph node

1.02 (0.98–1.08); 0.33

Positive lymph nodes

Yes versus no

3.96 (0.74–21.05); 0.11

PSA value RP

 + 1 unit

4.96 (0.35–69.85); 0.24

Adjuvant EBRT

Yes versus no

1.33 (0.43–4.18); 0.62

Prior ADT^d

Yes versus no

1.6 (0.64–4.02); 0.32

Ongoing ADT

Yes versus no

2.16 (0.58–8.04); 0.25

Salvage therapy

Yes versus no

0.63 (0.25–1.57); 0.32

PSA doubling time months

 + 1 month

0.98 (0.94–1.02); 0.26

PSA velocity

 + 1 unit

67.57 (1.56–2930.5); 0.03

PSA value

 + 1 unit

1.58 (1.02–2.45); 0.04